This page shows the latest OncoMed Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Dr Jeremy Bender joined from Allos as chief business officer, while Dr Aaron Sato joined from OncoMed Pharmaceuticals as VP, research.
575. Orexo/Ortho-McNeil-Janssen. Small molecules for COPD and asthma. Discovery. 574. Oncomed Pharmaceuticals/Bayer Schering. ... ElexoPharm/Merck &Co. Aldosterone synthase targets for cardiovascular disease. Discovery. 42. Adeona Pharmaceuticals/Meda.
UK pharmaceutical company GlaxoSmithKline (GSK) and US-based biotech OncoMed Pharmaceuticals have partnered to discover, develop and market antibody therapeutics to target cancer stem cells. ... GSK also has option to license four OncoMed product
More from news
Approximately 0 fully matching, plus 3 partially matching documents found.
Dr Jakob Dupont to leave the clinical-stage company. OncoMed Pharmaceuticals' Dr Jakob Dupont has resigned as senior vice president and chief medical officer, and is due to step down from ... Paul Hastings, OncoMed's chairman and chief executive officer,
He brings senior leadership experience in clinical development, compliance and licensing fromOncoMed Pharmaceuticals and PDL BioPharma, as well as academic experience from the University of North Carolina's Chapel Hill School
He was also heavily involved in the acquisition of Allos by Spectrum Pharmaceuticals. ... Dr Sato joins Sutro from OncoMed Pharmaceuticals, where he served as senior director of antibody engineering.
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...